Navigation Links
Researchers discover link between organ transplantation and increased cancer risk
Date:7/15/2008

PHILADELPHIA Researchers have determined a novel mechanism through which organ transplantation often leads to cancer, and their findings suggest that targeted therapies may reduce or prevent that risk.

In the July 15, 2008, issue of Cancer Research, researchers at Harvard Medical School found in animal and laboratory experiments that the anti-rejection, immunosuppressive drug cyclosporine ramps up expression of vascular endothelial growth factor (VEGF), which signals the growth of new blood vessels that can feed tumors.

They also found that simultaneously administering an anti-VEGF therapy with cyclosporine in mice repressed this tumor growth. Several inhibitors of VEGF are already in use in human cancer therapy.

The findings could offer some good news for the 15 to 20 percent of transplant patients who develop cancer within a decade of receiving new organs, according to the study's senior investigator, Soumitro Pal, Ph.D., an assistant professor at Harvard Medical School's Transplantation Research Center at Children's Hospital in Boston.

"It may be that anti-VEGF agents given judiciously after transplantation can reduce future cancer occurrence," he said.

VEGF expression is markedly increased in patients post-transplantation, and this can aid in the development of a blood supply to a transplanted organ, helping it survive and thrive. "But once the organ has stabilized, it may be possible to lower the level of VEGF expression to prevent tumor growth," he said. "We would need to figure out how to balance benefit and risk to keep cancer at bay."

Tumors that develop after transplantation may have three potential sources: they may have pre-existed or could have been a recurrence of previous cancer and in both of these cases, a patient's pre-transplant immune system might have kept these cancers in check or cancer-causing viruses could have come from the donor organ. Physicians have long observed that immunosuppressive agents, such as the class of calcineurin inhibitors that includes cyclosporine, appear to promote cancer development, often in organs that are not transplanted, but the cause of this was unclear. The Harvard team tested the ability of cyclosporine to promote growth of pre-existing tumors in mice implanted with human renal (kidney) cancer cells. Mice treated with the agent formed tumors faster than untreated mice, but anti-VEGF therapy substantially reduced that excessive growth.

Digging deeper into the biological pathway of VEGF activation, the scientists found that cyclosporine activates two of the three forms of the common protein catalyst, protein kinase C, which leads to increased expression of VEGF.

"We think PKC-mediated VEGF transcriptional activation is a key component in the progression of cyclosporine-induced post-transplantation cancer," Pal said. "It is likely not the whole story, but this gives us a clue that we might be able to use existing or novel therapies to reduce cancer risk in transplanted patients."


'/>"/>

Contact: Jeremy Moore
Jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related biology news :

1. Dartmouth researchers discover gene signatures for scleroderma
2. Louisiana Tech researchers feature drug reformulation in prestigious journal
3. UCLA researchers locate and image prostate cancer as it spreads to lymph nodes
4. Researchers catch ion channels in their opening act
5. UGA researchers discover mechanism that explains how cancer enzyme winds up on ends of chromosomes
6. Researchers hack final part of the immune system code
7. Iowa State researchers study ground cover to reduce impact of biomass harvest
8. From foe to friend: Researchers use salmonella as a way to administer vaccines in the body
9. Researchers reveal types of genes necessary for brain development
10. Researchers identify cancer preventive properties in common vitamin supplement
11. UT Southwestern researchers identify new targets for RNAs that regulate genes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... to provide their customers enhanced security to access ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
Breaking Biology News(10 mins):
(Date:5/27/2016)... New Jersey and ... Indegene ( http://www.indegene.com ... und marketingorientierten Lösungen für die Life-Science-Branche, Pharmaunternehmen ... ein bekannter weltweiter Anbieter von innovativen wissenschaftlichen ... Zuge des Starts von IntraScience heute den ...
(Date:5/26/2016)... , May 26, 2016 Q BioMed ... it will be a featured presenter at the 5th Annual ... New York City at the Grand Hyatt ... , Q BioMed Inc. CEO, is scheduled to begin at ... the company,s business strategy, recent developments and outline milestones for ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... are used in leading laboratories all over the globe. Their cute firefly logo ... to manufacturing awesome cuvettes, FireflySci makes spectrophotometer calibration standards that never require recalibration. ...
(Date:5/25/2016)... ... May 25, 2016 , ... Founder of the Fitzmaurice Hand ... and surgery of the hand by the National Board of Physicians and Surgeons, ... and beyond in his pursuit of providing the most comprehensive, effective treatment for ...
Breaking Biology Technology: